Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Prodarsan

Aandeel Pharming Group NL0010391025

Laatste koers (eur) Verschil Volume
0,836   -0,005   (-0,54%) Dagrange 0,836 - 0,850 2.518.302   Gem. (3M) 5,5M

Prodarsan

Volgen
2 Posts
| Omlaag ↓
  1. TonK_0 12 maart 2009 20:00
    Pharming says can fund Prodarsan costs
    by Aaron Gray-Block

    Last Updated: 2009-03-03 12:00:23 -0400 (Reuters Health)

    * Anti-ageing drug aims to delay DNA damage

    * Development costs significantly less than 100 mln euros

    * Initial market seen at 50 mln to 100 mln euros

    * Tests on premature-ageing patients this year

    AMSTERDAM (Reuters) - Dutch biotech firm Pharming said on Tuesday development costs for its anti-ageing drug Prodarsan will be significantly less than 100 million euros and estimated the market at 50 to 100 million euros in annual sales.

    Chief Commercial Officer Rein Strijker told Reuters in an interview the development costs for the drug are budgeted within the company's existing business plan and are significantly offset by grants and subsidies.

    Follow-on introductions and development for other markets will be financed by initial revenues.

    "We currently do not give guidance for the timing of market introductions as this is highly dependent on current discussions with regulatory bodies," Strijker said.

    Pharming has completed a phase I study of Prodarsan, a drug made by a subsidiary for those suffering from Cockayne syndrome or premature ageing, and is looking into other types of anti-ageing drugs to treat illnesses such as Alzheimer's Disease.

    "It's somewhat unlikely that we will be able to extend the lives of normally ageing people. It's different for premature ageing when you have a genetic defect. That's of course one of our hopes that we can extend lives," Strijker said.

    An analyst at SNS Securities said the coming results of clinical tests for Prodarsan are very important: "They need to show how effective it is, but initially, it looks like it can be very positive for Pharming," the analyst said.

    Pharming intends to start testing Prodarsan on patients of Cockayne syndrome this year once it has approval from regulatory authorities. Tests will be done in Europe and the United States.

    There is no known cure for Cockayne syndrome, a rare genetic disease, where children suffer from accelerated aging and which results in "growth failure, mental retardation, eye abnormalities and a reduced life expectancy," Pharming said.

    Besides Prodarsan, Strijker said other anti-ageing treatments in development may make people less susceptible to illnesses commonly associated with the elderly.

    Most human organs replace cells without problem, but there is a limited capacity to cell replacement and repair and at some point an organ's functioning worsens.

    Strijker said brain cells and hormone-producing organs are usually the first organs to show signs of damage and Pharming is working on treatments to slow down the damage process.

    "If you would be able to delay the onset of Alzheimer's by five years, the number of Alzheimer's patients would drop down 50 percent," he said.
    (Editing by David Cowell)

    Copyright Reuters 2009.
    www.hearingreview.com/reuters_article...
  2. [verwijderd] 17 januari 2010 20:19
    www.wirralnews.co.uk/wirral-news/loca...

    onderstaande is een''oud'' bericht... maar Prodarsan is dus ook al bekend!

    Specialists meet to discuss treatments for the rare disorder which affects Wallasey teenager Amy Garton-Hughes

    Sep 23 2009 by Lorna Hughes, Heswall News

    SPECIALISTS from around the world have met to discuss treatments for a rare disease which affects a Wallasey teenager.

    Amy Garton-Hughes, 17, mum Jayne Hughes and Mandi Elliot, a trustee for the Amy and Friends charity, visited Boston last week to attend a science conference for Cockayne Syndrome (CS), a rare and debilitating premature ageing disorder.

    The event was the first of its kind and was co-sponsored by Amy and Friends and American CS support group Share and Care.

    Delgates heard that the drug Prodarsan, which could slow down the ageing process and help the growth of children with CS, will begin trials later this month.

    Jayne said: “The meeting was amazing – the diagnosis procedure is changing in the UK and other parts of the world thanks to Amy's story, amongst others, and the trial for treatment has finally got the go ahead.

    “We are so very proud to be part of this ground-breaking research.”

    Find out more about the charity at www.amyandfriends.org
2 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Pharming stemt over nieuwe CEO
  2. Pharming presenteert nieuwe CEO
  3. Fundlogic verkoopt bijna geheel belang in Pharming
  4. Fundlogic flink groter in Pharming
  5. DWS meldt groter belang in Pharming
  6. Morgan Stanley groter in Pharming
  7. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  8. RBC verhoogt koersdoel Pharming fors
  9. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  10. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster